FRNM.US Freenome, Inc. Common stock

Healthcare Health Care Providers & Services USA Stocks
10.41 USD
Close of Nov 14, 2026
9.71 17.50
Market cap
USD 1.15B
P/E
-
P/B
2.44x
ROE
-20.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is FRNM.US undervalued?

Graham number

The Graham number of Freenome, Inc. Common stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Freenome, Inc. Common stock fundamental analysis

No fundamental analysis for Freenome, Inc. Common stock yet.

Freenome, Inc. Common stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Freenome, Inc. Common stock

Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen" CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as …

Full company profile